Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Short-term Investments (2018 - 2025)

AC Immune (ACIU) has disclosed Short-term Investments for 7 consecutive years, with $147.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Short-term Investments rose 432.86% to $147.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $147.5 million, a 432.86% increase, with the full-year FY2024 number at $147.5 million, up 439.51% from a year prior.
  • Short-term Investments was $147.5 million for Q4 2024 at AC Immune, up from $27.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $147.5 million in Q4 2024 to a low of $27.7 million in Q4 2023.
  • A 5-year average of $93.5 million and a median of $94.5 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 70.7% in 2023, then surged 432.86% in 2024.
  • AC Immune's Short-term Investments stood at $71.9 million in 2020, then skyrocketed by 74.97% to $125.8 million in 2021, then dropped by 24.91% to $94.5 million in 2022, then crashed by 70.7% to $27.7 million in 2023, then soared by 432.86% to $147.5 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Short-term Investments are $147.5 million (Q4 2024), $27.7 million (Q4 2023), and $94.5 million (Q4 2022).